MDXG
NASDAQ · Biotechnology
Mimedx Group Inc
$4.77
+0.08 (+1.71%)
Financial Highlights (FY 2026)
Revenue
411.02M
Net Income
47.69M
Gross Margin
82.6%
Profit Margin
11.6%
Rev Growth
+16.1%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.6% | 82.6% | 32.6% | 32.6% |
| Operating Margin | 15.3% | 13.7% | 14.0% | 14.5% |
| Profit Margin | 11.6% | 11.0% | 14.5% | 11.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 411.02M | 354.15M | 190.63M | 232.96M |
| Gross Profit | 339.34M | 292.38M | 62.11M | 75.91M |
| Operating Income | 62.72M | 48.64M | 26.66M | 33.71M |
| Net Income | 47.69M | 36.98M | 27.70M | 27.53M |
| Gross Margin | 82.6% | 82.6% | 32.6% | 32.6% |
| Operating Margin | 15.3% | 13.7% | 14.0% | 14.5% |
| Profit Margin | 11.6% | 11.0% | 14.5% | 11.8% |
| Rev Growth | +16.1% | +16.1% | +8.9% | +19.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 22.55M | 22.55M | 233.39M | 246.36M |
| Total Equity | 322.17M | 322.17M | 355.89M | 342.73M |
| D/E Ratio | 0.07 | 0.07 | 0.66 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 64.11M | 52.48M | 34.17M | 44.70M |
| Free Cash Flow | — | — | 29.04M | 38.48M |